N
9.67
-0.79 (-7.55%)
| Penutupan Terdahulu | 10.46 |
| Buka | 10.54 |
| Jumlah Dagangan | 225,733 |
| Purata Dagangan (3B) | 243,818 |
| Modal Pasaran | 144,369,232 |
| Harga / Jualan (P/S) | 223.36 |
| Harga / Buku (P/B) | 0.570 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 - 12 May 2025 |
| Margin Operasi (TTM) | -8,930.27% |
| EPS Cair (TTM) | -4.28 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.00% |
| Nisbah Semasa (MRQ) | 20.84 |
| Aliran Tunai Operasi (OCF TTM) | -70.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -49.42 M |
| Pulangan Atas Aset (ROA TTM) | -18.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Neurogene Inc. | Menurun | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.40 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.16% |
| % Dimiliki oleh Institusi | 108.35% |
| Julat 52 Minggu | ||
| Median | 50.00 (417.06%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 25 Mar 2025 | 50.00 (417.06%) | Beli | 14.20 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Apr 2025 | Pengumuman | Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome |
| 24 Mar 2025 | Pengumuman | Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates |
| 24 Feb 2025 | Pengumuman | Neurogene to Participate in Upcoming Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |